End-of-Life Care: Use of Antineoplastic Therapy and Nonessential Medications in Veteran Patients Receiving Palliative Care.
This study evaluated the incidence of antineoplastic therapy administration and use of nonessential medications at 30 and 14 days prior to death among patients with metastatic lung, prostate, colon, or pancreatic cancer who were also receiving palliative care. METHODS: Using retrospective chart review, this study evaluated patients admitted to a U.S. Department of Veterans Affairs healthcare system during a two-year period. Variables assessed included use of antineoplastic therapy and nonessential medications, emergency department visits, hospitalizations, palliative care accessibility, and hospice referrals. FIN...
Source: Clinical Prostate Cancer - November 21, 2020 Category: Cancer & Oncology Authors: Cullen G Tags: Clin J Oncol Nurs Source Type: research

68Ga-PSMA PET/CT With Incidental Finding of COVID-19 in an Asymptomatic Patient.
E, Rojas J Abstract A 70-year-old man with prostate adenocarcinoma was diagnosed by transrectal biopsy, with Gleason of 4 + 5 and initial PSA of 225 ng/mL since March 2020. Ga-PSMA PET/CT was performed as part of initial staging. The images showed an enlarged prostate with focal PSMA uptake in both lobes. Retroperitoneal and pelvic lymph nodes with moderate uptake of PSMA were shown. Another finding was a moderate PSMA uptake in the both lung parenchymas associated with opacities in CT. The patient denied any symptoms of coronavirus disease and was referred to the emergency department for RT-PCR COVID-19, and the...
Source: Clinical Prostate Cancer - November 11, 2020 Category: Cancer & Oncology Authors: Morón S, González E, Rojas J Tags: Clin Nucl Med Source Type: research

A randomized controlled trial of a home-based exercise program on prognostic biomarkers in men with prostate cancer: A study protocol.
This study will provide data on the feasibility of conducting a home-based exercise study and pilot data on the impact of exercise on circulating concentrations of biomarkers reported in the literature to be beneficial for the prognostication of PCa. Methods/design: Thirty male patients, clinically-diagnosed with prostate cancer under active surveillance, will be recruited to participate in a 2-arm, 24-week home-based program. Random allocation to each arm - intervention, and control - will be performed in a 1:1 ratio. Participants assigned to the intervention group will perform 30 min of light-to-moderate intens...
Source: Clinical Prostate Cancer - October 22, 2020 Category: Cancer & Oncology Authors: Patel DI, Gallegos AM, Sheikh B, Vardeman S, Liss MA Tags: Contemp Clin Trials Commun Source Type: research

Implementation of repeat biopsy and detection of cancer after a diagnosis of atypical small acinar proliferation of the prostate.
Abstract Current guidelines recommend a repeat biopsy within 3-6 months after an initial diagnosis of atypical small acinar proliferation (ASAP) due to the high incidence of cancer detection on repeat biopsy. The current study sought to investigate practice patterns after a diagnosis of ASAP in a real-world setting and examine the clinicopathological outcomes of repeat biopsy. The departmental database of the Hyogo Prefectural Nishinomiya Hospital identified 97 of 1,218 patients with a diagnosis of ASAP on initial biopsy from 2011 to 2016. Clinical and pathological data were retrospectively analyzed. Of the 97 pat...
Source: Clinical Prostate Cancer - October 6, 2020 Category: Cancer & Oncology Authors: Imanaka T, Yoshida T, Taniguchi A, Yamanaka K, Kishikawa H, Nishimura K Tags: Mol Clin Oncol Source Type: research

Long non-coding RNAs in prostate tumorigenesis and therapy (Review).
Abstract Prostate cancer (PCa) is one of the most frequently diagnosed malignancy. Although there have been many advances in PCa diagnosis and therapy, the concrete mechanism remains unknown. Long non-coding RNAs (lncRNAs) are novel biomarkers associated with PCa, and their dysregulated expression is closely associated with risk stratification, diagnosis and carcinogenesis. Accumulating evidence has suggested that lncRNAs play important roles in prostate tumorigenesis through relevant pathways, such as androgen receptor interaction and PI3K/Akt. The present review systematically summarized the potential clinical u...
Source: Clinical Prostate Cancer - October 3, 2020 Category: Cancer & Oncology Authors: Jiang G, Su Z, Liang X, Huang Y, Lan Z, Jiang X Tags: Mol Clin Oncol Source Type: research

ESTRO/ACROP IORT recommendations for intraoperative radiation therapy in primary locally advanced rectal cancer.
We report the ESTRO-ACROP (European Society for Radiotherapy and Oncology - Advisory Committee on Radiation Oncology Practice) recommendations for performing IORT in primary locally advanced rectal cancer. PMID: 33005755 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - October 3, 2020 Category: Cancer & Oncology Authors: Calvo FA, Sole CV, Rutten HJ, Poortmans P, Asencio JM, Serrano J, Aristu J, Roeder F, Dries WJ Tags: Clin Transl Radiat Oncol Source Type: research

PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018).
Abstract •PIVOTALboost evaluates benefits/toxicity of pelvic node RT and focal boost dose escalation.•Unfavourable intermediate/high risk and bulky local disease are most likely to benefit.•Functional MRI imaging is used to select patients for different types of dose escalation.•HDR brachytherapy or focal dose escalation with IMRT are used as options.•Training and support is provided to reduce variations of contouring and radiotherapy planning.•The trial is recruiting patients in 38 radiotherapy centres through the UK. PMID: 32995575 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - October 2, 2020 Category: Cancer & Oncology Authors: Syndikus I, Cruickshank C, Staffurth J, Tree A, Henry A, Naismith O, Mayles H, Snelson N, Hassan S, Brown S, Porta N, Griffin C, Hall E Tags: Clin Transl Radiat Oncol Source Type: research

Utility of a Fifth-Generation Ultrasensitive Prostate-Specific Antigen Assay for Monitoring Prostate Cancer Patients after Radical Prostatectomy with 3 Years of Follow-Up.
Abstract BACKGROUND: We investigated an ultrasensitive prostate-specific antigen (uPSA) immunoassay (MesoScale; lower limit of detection (LLD) of 0.0035 pg/mL) to monitor patients with prostate cancer (PCa) following radical prostatectomy (RP) and to examine whether changes in PSA in the conventionally undetectable range (
Source: Clinical Prostate Cancer - September 30, 2020 Category: Cancer & Oncology Authors: Ren AH, Soosaipillai A, Mathew A, Nikolenko G, Sardesai L, Stengelin M, Diamandis EP Tags: Clin Chem Source Type: research

The botanical component p-hydroxycinnamic acid suppresses the growth and bone metastatic activity of human prostate cancer PC-3 cells in vitro.
Abstract Bone metastatic prostate cancer is one of the most common malignancies in developed countries and the second leading cause of cancer-related death in men. There remains no effective treatment for metastatic prostate cancer. We investigate here the anticancer effects of botanical component p-hydroxycinnamic acid (HCA) on the PC-3 cells in vitro model of bone metastatic human prostate cancer. Culturing with HCA (10-1000 nM) suppressed colony formation and growth of PC-3 cells. Mechanistically, culturing with HCA decreased protein levels of Ras, PI3K, Akt, MAPK, NF-κB p65 and β-catenin relate...
Source: Clinical Prostate Cancer - September 30, 2020 Category: Cancer & Oncology Authors: Yamaguchi M, Murata T, Ramos JW Tags: J Cancer Res Clin Oncol Source Type: research

Lymphedema: Clinical Summary of the ONS Guidelines ™ for Cancer Treatment-Related Lymphedema.
Lymphedema: Clinical Summary of the ONS Guidelines™ for Cancer Treatment-Related Lymphedema. Clin J Oncol Nurs. 2020 Oct 01;24(5):566-570 Authors: Backler C, Beck M, Poage E Abstract Secondary (acquired) lymphedema is a chronic condition lacking a known cure that most commonly results from cancer treatment, particularly for breast, gynecologic, prostate, and head and neck cancers; lymphoma; and melanoma, and affects an estimated 1 in 1,000 Americans. Lymphedema is characterized by an accumulation of protein-rich lymphatic fluid in the affected part of the body. It can potentially affect function...
Source: Clinical Prostate Cancer - September 21, 2020 Category: Cancer & Oncology Authors: Backler C, Beck M, Poage E Tags: Clin J Oncol Nurs Source Type: research

Intra-arterial injection to create bone metastasis of prostate cancer in mice.
Abstract Human prostate cancer often metastasizes to the bone, but the mechanisms are not quite clear. The difficulties in studying the biology of bone metastasis are due to lack of animal models with high frequency of bone metastases. In the present study, we tested two intra-arterial injection methods, i.e., intra-caudal artery injection and intra-femoral artery injection. Mouse prostate cancer cell line MPC3-luc was injected into C57BL/6J male mice via intra-caudal artery injection (n = 8) or intra-femoral artery injection (n = 11). We found one mouse developed metastatic tumors in both hind limbs and the tail ...
Source: Clinical Prostate Cancer - September 18, 2020 Category: Cancer & Oncology Authors: Zhong L, Miller HD, Zhang Y, Jin B, Ge D, You Z Tags: Am J Clin Exp Urol Source Type: research

Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in TP53, PTEN and RB1 on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancer.
CONCLUSIONS: This study identified a unique molecular signature consisting of combined aberrations in TP53, PTEN and RB1 that is associated with poorer overall survival, as well as increasing prevalence of ETS gene fusions and differential gene expression patterns favoring aggressive disease and tumor progression. Identification of this subset of patients could inform prognostic decisions and provide a rationale for more aggressive or unique therapeutic approaches. PMID: 32929406 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 18, 2020 Category: Cancer & Oncology Authors: Watson AP, Shabaneh A, Wang J, Dehm SM, Rao A, Ryan CJ Tags: Am J Clin Exp Urol Source Type: research

Genome and transcriptome profiling of FBXW family in human prostate cancer.
Abstract F-box and WD repeat domain containing (FBXW) family of E3 ligases has 10 members that ubiquitinate substrate proteins for proteasome-mediated degradation. Publicly archived datasets from The Cancer Genome Atlas (TCGA), Prostate Cancer Transcriptome Atlas (PCTA), and cBioPortal were analyzed for mRNA expression and genetic alterations of 10 FBXW genes. We found that FBXW7 mRNA expression was significantly decreased in primary prostate cancers compared to normal prostate tissues, whereas mRNA expression of FBXW8-10 was significantly increased in primary prostate cancers compared to normal prostate tissues. ...
Source: Clinical Prostate Cancer - September 18, 2020 Category: Cancer & Oncology Authors: Lan R, Jin B, Liu YZ, Zhang K, Niu T, You Z Tags: Am J Clin Exp Urol Source Type: research

BETting on next-generation bromodomain inhibitors.
Abstract Within the last decade, bromodomain and extraterminal (BET) domain inhibitors were introduced as the first in a wave of new agents known as bromodomain inhibitors. These original examples exhibited anti-inflammatory and anticancer properties, and some have progressed to human clinical trials. BET proteins and their conserved N-terminal bromodomains, BD1 and BD2, have been implicated in the regulation of transcription. The early-generation BET inhibitors showed equal affinity for BD1 and BD2, and therefore the differential roles of BD1 and BD2 remain poorly understood. A recent study published in Science b...
Source: Clinical Prostate Cancer - September 18, 2020 Category: Cancer & Oncology Authors: Collins MK, Chau CH, Price DK, Figg WD Tags: Am J Clin Exp Urol Source Type: research

Distinct cell-types in the prostate share an aging signature suggestive of metabolic reprogramming.
Abstract Age is a significant risk factor for disease of the prostate. However, the mechanisms by which age increases disease risk have not been well described. We previously reported age-related changes within the inflammatory and luminal compartments of the mouse prostate. Old mouse prostates exhibit an expansion of the population of Trop2+ luminal progenitor cells and a reduction in the frequency and functional capacity of Trop2- luminal cells, indicating that different cell-types have distinct responses to aging. Whether distinct cell-types in the prostate share a common signature of aging has not been establi...
Source: Clinical Prostate Cancer - September 18, 2020 Category: Cancer & Oncology Authors: Crowell PD, Giafaglione JM, Hashimoto T, Goldstein AS Tags: Am J Clin Exp Urol Source Type: research

Total and added sugar intakes, sugar types, and cancer risk: results from the prospective NutriNet-Sant é cohort.
CONCLUSIONS: These results suggest that sugars may represent a modifiable risk factor for cancer prevention (breast in particular), contributing to the current debate on the implementation of sugar taxation, marketing regulation, and other sugar-related policies. This trial was registered at clinicaltrials.gov as NCT03335644. PMID: 32936868 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 15, 2020 Category: Cancer & Oncology Authors: Debras C, Chazelas E, Srour B, Kesse-Guyot E, Julia C, Zelek L, Agaësse C, Druesne-Pecollo N, Galan P, Hercberg S, Latino-Martel P, Deschasaux M, Touvier M Tags: Am J Clin Nutr Source Type: research

Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Abstract Management of non-metastatic castration-resistant prostate cancer (nmCRPC) has undergone a paradigm shift with next-generation androgen receptor inhibitors. However, direct comparative data are not available to inform treatment decisions and/or guideline recommendations. Therefore, we performed network meta-analysis to indirectly compare the efficacy and safety of currently available treatments. Multiple databases were searched for articles published before June 2020. Studies that compared overall and/or metastasis-free and/or prostate-specific antigen (PSA) progression-free survival (OS/MFS/PSA-PFS) and/...
Source: Clinical Prostate Cancer - September 13, 2020 Category: Cancer & Oncology Authors: Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuettfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF Tags: Int J Clin Oncol Source Type: research

Sympathetic and parasympathetic innervation in cancer: therapeutic implications.
CONCLUSIONS: Sympathetic nerves innervating the tumor microenvironment promote cancer progression and are related to stress-induced cancer behavior. The parasympathetic/vagal nerves have variable (promoting or suppressing) effects on different cancer types. Approaches directed toward the sympathetic and parasympathetic/vagal nerves can be developed as a new cancer therapy. In addition to existing pharmacological, surgical, and electrical approaches, a recently developed virus vector-based genetic local neuroengineering technology is a powerful approach that selectively manipulates specific types of nerve fibers innervating...
Source: Clinical Prostate Cancer - September 13, 2020 Category: Cancer & Oncology Authors: Kamiya A, Hiyama T, Fujimura A, Yoshikawa S Tags: Clin Auton Res Source Type: research

Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice.
Abstract AIM: To document cancer yields of magnetic resonance imaging (MRI)-directed biopsies in men with suspected prostate cancer referred to secondary care. MATERIALS AND METHODS: Men with suspected cancer undergoing multiparametric prostate MRI as the first-line investigation were included in the present study. Systematic transrectal prostate biopsies with/without cognitive targeted biopsies were performed. Diagnostic yields of International Society of Urological Pathology (ISUP) ≥2 cancers by the Prostate Imaging Reporting and Data System (PI-RADS) category were recorded. Impacts of prostate-specific ...
Source: Clinical Prostate Cancer - September 8, 2020 Category: Cancer & Oncology Authors: Sokhi HK, Padhani AR, Patel S, Pope A Tags: Clin Radiol Source Type: research

Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment.
PMID: 32897829 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 7, 2020 Category: Cancer & Oncology Authors: Schweizer MT, Cheng HH, Nelson PS, Montgomery RB Tags: J Clin Oncol Source Type: research

Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide.
CONCLUSION: We found that the proportion of progressing lesions was low, indicating that a substantial number of lesions appear to continue to benefit from enzalutamide beyond progression. Selective targeting of nonresponding lesions may be a reasonable approach to extend benefit. PMID: 32897830 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 7, 2020 Category: Cancer & Oncology Authors: Kyriakopoulos CE, Heath EI, Ferrari A, Sperger JM, Singh A, Perlman SB, Roth AR, Perk TG, Modelska K, Porcari A, Duggan W, Lang JM, Jeraj R, Liu G Tags: J Clin Oncol Source Type: research

Efficacy of abiraterone acetate in castration-resistant metastatic prostate cancer: A real-world data analysis.
CONCLUSIONS: These results show that abiraterone acetate is an effective and reliable agent in real-life data. PMID: 32892496 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 4, 2020 Category: Cancer & Oncology Authors: Oyman A, Başak M, Özçelik M, Özyükseler DT, Işık S, Yıldırım ME Tags: Asia Pac J Clin Oncol Source Type: research

Stability of daily rectal movement and effectiveness of replanning protocols for sparing rectal doses based on the daily CT images during proton treatment for prostate cancer.
CONCLUSION: Our data demonstrate that the daily movement of the rectal anterior side tends to move toward the anterior side, which results in a rectal overdose, and the mean of the movement gradually decreases with the passage of days. In such cases, replanning with the reference CT after 10 days is effective to spare the rectal dose. PMID: 32888359 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 4, 2020 Category: Cancer & Oncology Authors: Maeda Y, Sato Y, Yamamoto K, Tamamura H, Sasaki M, Fuwa N, Takamatsu S, Kume K Tags: J Appl Clin Med Phys Source Type: research

Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
CONCLUSIONS: In this prematurely closed trial, we observed an unexpected high rate of termination of AS and an increased toxicity related to PSI. Patients hesitated to be randomized in a multi-arm trial. The optimal treatment of low and early-intermediate risk PCa remains unclear. PMID: 32886212 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 3, 2020 Category: Cancer & Oncology Authors: Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M Tags: J Cancer Res Clin Oncol Source Type: research

Degarelix as a neoadjuvant hormonal therapy for acute urinary tract toxicity associated with external beam radiotherapy for intermediate- and high-risk prostate cancer: a propensity score matched analysis.
CONCLUSIONS: Luteinizing hormone-releasing hormon antagonists may reduce acute urinary tract toxicity during prostate cancer external beam radiotherapy compared with luteinizing hormone-releasing hormon agonists, in particular in patients with moderate to severe symptoms at the start of treatment. PMID: 32875317 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 1, 2020 Category: Cancer & Oncology Authors: Hata S, Shin T, Abe S, Kawano K, Sato R, Kai T, Shibuya T, Ando T, Mimata H Tags: Jpn J Clin Oncol Source Type: research

Latent prostate cancer among Japanese males: a bibliometric study of autopsy reports from 1980-2016.
Abstract Prostate cancer is one of the most common malignancies, but a substantial portion remains latent throughout the patients' lifetime. Analysis of temporal change in the latent prostate cancer pool would be beneficial for clinical decision-making, but longitudinal autopsy studies are rare. We conducted a hand-search of the Annual of Pathological Autopsy Cases in Japan from 1980 to 2016 for cases of latent prostate cancer. Of 570 997 males aged 30 or older, latent prostate cancer was detected in 12 562 patients (2.2%). Proportion of detected cases correlated strongly with 'aging rate', the percentag...
Source: Clinical Prostate Cancer - September 1, 2020 Category: Cancer & Oncology Authors: Takeshima Y, Suzuki M, Miyakawa J, Tsuru I, Yamada Y, Nakamura M, Sato Y, Kawai T, Yamada D, Morikawa T, Kume H Tags: Jpn J Clin Oncol Source Type: research

Gene of the month: TMPRSS2 (transmembrane serine protease 2).
Abstract Transmembrane serine protease 2 is encoded by the TMPRSS2 gene. The gene is widely conserved and has two isoforms, both being autocatalytically activated from the inactive zymogen form. A fusion gene between the TMPRSS2 gene and ERG (erythroblast-specific-related gene), an oncogenic transcription factor, is the most common chromosomal aberration detected in prostate cancer, responsible for driving carcinogenesis. The other key role of TMPRSS2 is in priming the viral spike protein which facilitates viral entry essential for viral infectivity. The protease activates a diverse range of viruses. Both SARS-CoV...
Source: Clinical Prostate Cancer - August 31, 2020 Category: Cancer & Oncology Authors: Thunders M, Delahunt B Tags: J Clin Pathol Source Type: research

MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?
z P, Casquero F Abstract MRI-detected T3a prostate cancer is a heterogeneous disease. This post-hoc analysis of a prospective trial found that patients with T3a disease presenting obliteration of the recto-prostatic angle, contact-asymmetry of neuro-vascular bundle and periprostatic fat invasion, may be at higher risk of biochemical failure and metastases. PMID: 32875127 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - August 31, 2020 Category: Cancer & Oncology Authors: Gomez-Iturriaga A, Büchser D, Miguel IS, Marban M, Urresola A, Ezquerro A, Gil A, Suarez F, Gonzalez A, Mairata E, Martinez-Indart L, Cacicedo J, Couñago F, Mínguez P, Casquero F Tags: Clin Transl Radiat Oncol Source Type: research

Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
CONCLUSIONS: Our study demonstrated that a shorter PSADT, a heavier volume of bone metastases, and a later treatment line before Ra-223 are poor prognostic factors for mCRPC patients. These newly discovered risk factors may help select patients who potentially have long-term OS after Ra-223 treatment. PMID: 32875513 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - August 31, 2020 Category: Cancer & Oncology Authors: Yamamoto Y, Okuda Y, Kanaki T, Tanaka R, Nagahara A, Nakai Y, Nakayama M, Kakimoto KI, Nishimura K Tags: Int J Clin Oncol Source Type: research

Association of gene polymorphisms of KLK3 and prostate cancer: A meta-analysis.
Abstract Previous studies have suggested that prostate-specific antigen (PSA) plays a role in the etiology of prostate cancer (PCa), and that polymorphisms of KLK3 may be associated with PCa. However, these results were conflicting. Therefore, we performed a meta-analysis to illuminate this problem. We searched the PubMed and Web of Science databases. Ten single nucleotide polymorphisms (SNPs) were involved in this meta-analysis. The pooled results showed that the minor alleles of rs1058205, rs2735839, rs174776, rs17632542, rs266849, rs266878, and rs2569735 were significantly associated with PCa. Compared to genot...
Source: Clinical Prostate Cancer - August 31, 2020 Category: Cancer & Oncology Authors: Li H, Fei X, Shen Y, Wu Z Tags: Adv Clin Exp Med Source Type: research

BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?
PMID: 32870734 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - August 31, 2020 Category: Cancer & Oncology Authors: Markowski MC, Antonarakis ES Tags: J Clin Oncol Source Type: research

Coronary Artery Bypass Grafting in Cancer Patients: Prevalence and Outcomes in the United States.
Abstract OBJECTIVE: To characterize the contemporary efficacy and utilization patterns of coronary artery bypass grafting (CABG) in specific cancer types. METHODS: We leveraged the data from the National Inpatient Sample and plotted trends of utilization and outcomes of isolated CABG (with no other additional surgeries during the same hospitalization) procedures from January 1, 2003, through September 1, 2015. Propensity score matching was used to assess for potential differences in outcomes by type of cancer status among contemporary (2012-2015) patients. RESULTS: Overall, the utilization of CABG decrea...
Source: Clinical Prostate Cancer - August 31, 2020 Category: Cancer & Oncology Authors: Guha A, Dey AK, Kalra A, Gumina R, Lustberg M, Lavie CJ, Sabik JF, Addison D Tags: Mayo Clin Proc Source Type: research

Current status of PSMA PET imaging in prostate cancer.
Abstract The past decade has witnessed the rising popularity and acceptance of molecular definitions on disease management. Prostate-specific membrane antigen (PSMA), in light of its molecular nature and cytokinetic properties, has rapidly become the target for development of a variety of functional tracers for PET/CT evaluation of prostate cancer. The most commonly used PSMA-binding analog is 68 Ga-labeled PSMA-11, which is now widely applied in both research and clinical settings. Literature data in the recent years have been enriched by a number of meta-analyses and systemic reviews on the evolving role of PSMA...
Source: Clinical Prostate Cancer - August 29, 2020 Category: Cancer & Oncology Authors: Ho CL, Wu KK, Chen S Tags: Asia Pac J Clin Oncol Source Type: research

Optimizing skeletal-related events prevention in patients with advanced prostate cancer.
Abstract In patients with metastatic castration-resistant prostate cancer (mCRPC), bone is a dominant site of metastasis. Bone metastases often lead to skeletal-related events (SREs), which include pain, spinal cord compression and fractures. The treatment of bone metastases in men with mCRPC aims to improve SRE-free survival, quality of life and clinical outcomes. Effective treatment options include antiresorptive bone-targeted agents such as zoledronic acid and denosumab, and radium-223, a bone-targeting radiopharmaceutical. Although overseas and local guidelines have widely recommended using either zoledronic a...
Source: Clinical Prostate Cancer - August 29, 2020 Category: Cancer & Oncology Authors: Leung AK Tags: Asia Pac J Clin Oncol Source Type: research

Feasibility and safety of 1.5  T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes.
We present preliminary data of the first older cancer patients treated with Hybrid Linac for stereotactic body radiotherapy (SBRT) consisting of 1.5 T MRI-guided and daily-adapted treatment. The aim was to assess feasibility, safety and the role of G8 and Charlson Comorbidity Index (CCI) questionnaires in predicting patients' QoL, evaluated by patient-reported outcome measures (PROMs). METHODS: Two groups of patients with localized prostate cancer or abdominal-pelvic oligometastases were analyzed. SBRT schedule consisted of 35 Gy delivered in 5 fractions. The primary endpoint was to measure the impact of G8 ...
Source: Clinical Prostate Cancer - August 13, 2020 Category: Cancer & Oncology Authors: Mazzola R, Figlia V, Rigo M, Cuccia F, Ricchetti F, Giaj-Levra N, Nicosia L, Vitale C, Sicignano G, De Simone A, Naccarato S, Ruggieri R, Alongi F Tags: J Cancer Res Clin Oncol Source Type: research

PROLAPSE: survey about local prostate cancer relapse salvage treatment with external beam re-irradiation: results of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
CONCLUSION: This first AIRO survey about salvage prostate re-EBRT provides an interesting snapshot and suggests increasing interest in re-EBRT patients in Italy. Consensus about some aspects of patients' selection, the necessity of biopsy, fractionation, and highly selective techniques seems feasible, but other key points such as irradiated volume, dosimetry parameters, and hormonal treatment association need to be clarified. PMID: 32583236 [PubMed - indexed for MEDLINE] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - August 13, 2020 Category: Cancer & Oncology Authors: Zerini D, Jereczek-Fossa BA, Ciabattoni A, Mirri A, Bertoni F, Fersino S, D'Agostino G, Lohr F, Mortellaro G, Triggiani L, Marvaso G, Pepa M, Cuccia F, Alongi F, Italian Association of Radiotherapy, Clinical Oncology (AIRO) Tags: J Cancer Res Clin Oncol Source Type: research

Transient acute kidney injury observed immediately after robot-assisted radical prostatectomy but not after open radical prostatectomy.
Abstract Acute kidney injury (AKI) is a serious postoperative complication that occurs following laparoscopic surgery. However, its association with robot-assisted radical prostatectomy (RARP), the gold standard surgery for prostate cancer, is controversial. The current cohort included 257 patients with prostate cancer who underwent either RARP (n=187) or open radical prostatectomy (ORP; n=70). Patient serum creatinine concentration was measured at the following six time points: Prior to surgery, on postoperative day 0 (immediately after surgery), on postoperative day 1, 3 months after surgery, 1 year after surger...
Source: Clinical Prostate Cancer - August 13, 2020 Category: Cancer & Oncology Authors: Naito A, Taguchi S, Suzuki M, Kawai T, Uchida K, Fujimura T, Fukuhara H, Kume H Tags: Mol Clin Oncol Source Type: research

Response to 'Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer'.
PMID: 32637660 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 10, 2020 Category: Cancer & Oncology Authors: Slevin F, Rodda SL, Bownes P, Murray L, Bottomley D, Melody C, Adiotomre E, Al-Qaisieh B, Dugdale E, Hulson O, Mason J, Smith J, Henry AM Tags: Clin Transl Radiat Oncol Source Type: research

A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study.
Discussion: The goal of this trial is to determine the potential benefit of ALA-SFC in patients who undergo LDR-BT. To the best of our knowledge, this is the first study investigating the potential clinical benefit of oral ALA-SFC after radiotherapy. More evidence from a further randomized controlled trial is needed to change the standard of care and lead to better post-radiotherapy management. Trial registration: This clinical trial was prospectively registered with the Japan Registry of Clinical Trials on 5 December 2019. The reference number is jRCTs051190077, nara0013 (Certified Review Board of Nara Medical Univer...
Source: Clinical Prostate Cancer - July 10, 2020 Category: Cancer & Oncology Authors: Miyake M, Tanaka N, Asakawa I, Yamaki K, Inoue T, Suzuki S, Hori S, Nakai Y, Anai S, Torimoto K, Toritsuka M, Nakagawa H, Tsukamoto S, Fujii T, Ohbayashi C, Hasegawa M, Kasahara M, Fujimoto K Tags: Contemp Clin Trials Commun Source Type: research

PSA decay during salvage radiotherapy for prostate cancer as a predictor of disease outcome - 5  year follow-up of a prospective observational study.
Conclusion: The addition of k to established clinical variables significantly improves the possibility to predict treatment outcome after SRT and could be used to personalize future therapies. PMID: 32613088 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 4, 2020 Category: Cancer & Oncology Authors: Gunnlaugsson A, Kjellén E, Bratt O, Ahlgren G, Johannesson V, Blom R, Nilsson P Tags: Clin Transl Radiat Oncol Source Type: research

Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer.
PMID: 32596516 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 1, 2020 Category: Cancer & Oncology Authors: Yamazaki H, Masui K, Suzuki G, Yoshida K Tags: Clin Transl Radiat Oncol Source Type: research

Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.
CONCLUSION: This study documents significant differences in key molecular events in PCA in Middle Eastern population compared to Western populations that could explain differences in PCA incidence, progression and prognostication. ERG, PTEN and SPINK1 genomic alteration occur less frequently and the enrichment of ERG for PTEN loss is not observed. Additionally, patients with combined PTEN loss/ERG positive are at highest risk for BCR vs North American Caucasian population where PTEN loss alone seems to be associated with the worst clinical outcome. The data presented here further support differences in clonal evolution bet...
Source: Clinical Prostate Cancer - June 17, 2020 Category: Cancer & Oncology Authors: Abdelsalam RA, Khalifeh I, Box A, Kalantarian M, Ghosh S, Abou-Ouf H, Lotfi T, Shahait M, Palanisamy N, Bismar TA Tags: J Cancer Res Clin Oncol Source Type: research

Risk of second primary cancers in individuals diagnosed with index smoking- and non-smoking- related cancers.
CONCLUSION: We found that 1-in-11 cancer survivors developed a SPC. Given the increasing number of cancer survivors and the importance of SPC as a cause of cancer death, there is a need for increased screening for and prevention of SPC. PMID: 32356175 [PubMed - indexed for MEDLINE] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 17, 2020 Category: Cancer & Oncology Authors: Adjei Boakye E, Wang M, Sharma A, Jenkins WD, Osazuwa-Peters N, Chen B, Lee M, Schootman M Tags: J Cancer Res Clin Oncol Source Type: research

Older age and comorbidity in breast cancer: is RT alone the new therapeutic frontier?
CONCLUSIONS: In older patients, ET did not show a benefit in terms of overall survival. Further studies focusing on tailored treatment approaches are warranted to offer the best care in terms of adjuvant treatment to these patients. PMID: 32405744 [PubMed - indexed for MEDLINE] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 17, 2020 Category: Cancer & Oncology Authors: La Rocca E, Meneghini E, Lozza L, Fiorentino A, Vitullo A, Giandini C, Bonfantini F, Di Cosimo S, Gennaro M, Sant M, Pignoli E, Valdagni R, De Santis MC Tags: J Cancer Res Clin Oncol Source Type: research

Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac.
Conclusions: Prostate MRgART can be delivered using the a high field MR-linac. Radiotherapy performed on a C-arm linac offers a good solution for prostate cancer patients who present with favourable anatomy at the time of reference imaging and demonstrate stable anatomy throughout the course of their treatment. For patients with critical OARs abutting target volumes on their reference image we have demonstrated the potential for a target dose coverage improvement for MRgART compared to C-arm linac treatment. PMID: 32395640 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - May 14, 2020 Category: Cancer & Oncology Authors: Dunlop A, Mitchell A, Tree A, Barnes H, Bower L, Chick J, Goodwin E, Herbert T, Lawes R, McNair H, McQuaid D, Mohajer J, Nilawar R, Pathmanathan A, Smith G, Hanson I, Nill S, Oelfke U Tags: Clin Transl Radiat Oncol Source Type: research

Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer.
Conclusion: Focal salvage HDR brachytherapy may provide good biochemical control with a low risk of severe toxicity. Further evaluation within clinical trials are needed to establish its role in the management of locally recurrent prostate cancer. PMID: 32368626 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - May 7, 2020 Category: Cancer & Oncology Authors: Slevin F, Hodgson S, Rodda SL, Bownes P, Bottomley D, Adiotomre E, Al-Qaisieh B, Dugdale E, Hulson O, Mason J, Smith J, Henry AM Tags: Clin Transl Radiat Oncol Source Type: research

Ligand-Mediated Targeting of Cytokine Interleukin-27 Enhances Its Bioactivity In  Vivo.
We describe our findings on the effects of targeted IL-27 gene delivery on prostate cancer cells in vitro and in vivo and how the targeting enhances bioactivity of the IL-27 cytokine. We applied the IL-27 gene delivery protocol utilizing sonoporation (sonodelivery) with the goal of reducing prostate tumor growth in an immunocompetent TC2R C57/BL6 model. The reduction in tumor growth and effector cellular profiles implicate targeted IL-27 as more effective than an untargeted version of IL-27 in promoting bioactivity, as assessed by STAT1 and IFN-γ reporter genes. Moreover, enhanced antitumor effects and sign...
Source: Clinical Prostate Cancer - May 1, 2020 Category: Cancer & Oncology Authors: Figueiredo ML, Figueiredo Neto M, Salameh JW, Decker RE, Letteri R, Chan-Seng D, Emrick T Tags: Mol Ther Methods Clin Dev Source Type: research

Corticosteroids alleviate adverse events associated with enzalutamide in patients with metastatic castration-resistant prostate cancer.
Abstract The aim of the present study was to investigate the impact of the combined use of corticosteroid on adverse events (AEs) induced by enzalutamide (Enz) in patients with metastatic castration-resistant prostate cancer (mCRPC). The cohort of the present study included 121 consecutive patients with mCRPC who sequentially received androgen receptor-axis-targeted (ARAT) agents, abiraterone acetate (AA) and Enz, in any order, without prior docetaxel therapy. Detailed assessments of AEs during treatment with Enz were conducted according to whether or not corticosteroid was administered. Of these patients, 63 and ...
Source: Clinical Prostate Cancer - April 8, 2020 Category: Cancer & Oncology Authors: Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H Tags: Mol Clin Oncol Source Type: research

Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09.
Conclusions: The results of this analysis show differences between PBS and PS/US with regards to two-fold MID changes in urinary function at 12 months, but no differences for average score declines over time. Future studies evaluating PRO measures between the two PBT modalities are warranted. PMID: 32258443 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 8, 2020 Category: Cancer & Oncology Authors: Mishra MV, Khairnar R, Bentzen SM, Larson G, Tsai H, Sinesi C, Vargas C, Laramore G, Rossi C, Rosen L, Sun K, Hartsell W Tags: Clin Transl Radiat Oncol Source Type: research

Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer.
Conclusions: Current RT with RTOG-based nodal fields for PCN+ provides good in-field tumour control, but frequent out-field nodal recurrences suggest missed microscopic locations. Expanding elective fields to include the aorta bifurcation may prolong recurrence-free survival. Future research must address whether the potential benefits of this strategy outbalance additional toxicity. PMID: 32154392 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 12, 2020 Category: Cancer & Oncology Authors: Liskamp CP, Donswijk ML, van der Poel HG, Schaake EE, Vogel WV Tags: Clin Transl Radiat Oncol Source Type: research